Literature DB >> 2993928

Effects of the irreversible alpha-adrenoceptor antagonists phenoxybenzamine and benextramine on the effectiveness of nifedipine in inhibiting alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in pithed rats.

P B Timmermans, M J Thoolen, M J Mathy, B Wilffert, A de Jonge, P A van Zwieten.   

Abstract

In pithed normotensive rats, i.v. injection of the selective alpha 1-adrenoceptor agonist cirazoline produced vasoconstriction which was largely resistant to inhibition by nifedipine. On the other hand, the pressor effects of the selective alpha 1-adrenoceptor agonists St 587 and Sgd 101/75 were much more effectively blocked by nifedipine, although not as effectively as the pressor effects to the selective alpha 2-adrenoceptor agonist B-HT 920. The sensitivity to inhibition of vasoconstriction in pithed rats to the different agonists increased in the order cirazoline much less than St 587 less than Sgd 101/75 less than B-HT 920. Phenoxybenzamine (3-300 micrograms/kg, i.v., -60 min) irreversibly antagonized the vasoconstriction to cirazoline, St 587, Sgd 101/75 and B-HT 920. After treatment of the rats with phenoxybenzamine the potency and efficacy of nifedipine in antagonizing vasoconstriction to alpha 1-, but not to alpha 2-adrenoceptor activation was dose-dependently enhanced. The potency of nifedipine to inhibit alpha 1-adrenoceptor-mediated vasoconstriction by cirazoline, St 587 and Sgd 101/75 was increased maximally to the level of efficacy at which nifedipine antagonized B-HT 920-induced vasoconstriction. The dose of phenoxybenzamine required to maximally increase the potency and efficacy of nifedipine to antagonize vasoconstriction of the alpha 1-adrenoceptor agonists was inversely related to the level of sensitivity to blockade by nifedipine of the vasoconstriction they produced. In contrast, pretreatment of rats with the irreversible antagonist, benextramine (10 mg/kg, i.v., -100 to -60 min) did not increase the potency or efficacy of nifedipine to antagonize vasoconstriction to cirazoline, St 587, Sgd 101/75 or B-HT 920, despite irreversible blockade of alpha 1- and alpha 2-adrenoceptors. These data suggest that phenoxybenzamine, but not benextramine, selectively inhibits the alpha 1-adrenoceptor mediated vasoconstrictor mechanism that is independent of influx of extracellular calcium. Moreover, the results show that the existence of receptor reserve or the number of alpha 1-adrenoceptors activated does not determine the relative contribution of calcium influx-independent mechanisms in alpha 1-adrenoceptor-mediated vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993928     DOI: 10.1007/bf00496376

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  49 in total

1.  l-1,2,3,4-Tetrahydro-8-methoxy-5-(methylthio)-2-naphthalenamine: a potent and selective agonist at alpha 1-adrenoceptors.

Authors:  R M DeMarinis; J P Hieble
Journal:  J Med Chem       Date:  1983-09       Impact factor: 7.446

2.  Differential interactions of clonidine and methoxamine with the postsynaptic alpha-adrenoceptor of rabbit main pulmonary artery.

Authors:  M I Holck; C H Jones; G Haeusler
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

3.  Phenoxybenzamine and dibenamine interactions with calcium channel effectors of the muscarinic receptor.

Authors:  E El-Fakahany; E Richelson
Journal:  Mol Pharmacol       Date:  1981-11       Impact factor: 4.436

4.  Review important concepts of receptor theory.

Authors:  R R Ruffolo
Journal:  J Auton Pharmacol       Date:  1982-12

5.  Inhibition of dopamine-stimulated adenylate cyclase activity by phenoxybenzamine.

Authors:  K G Walton; P Liepmann; R J Baldessarini
Journal:  Eur J Pharmacol       Date:  1978-11-15       Impact factor: 4.432

6.  Receptor interactions of imidazolines. IX. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist.

Authors:  R R Ruffolo; J E Waddell
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

7.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

8.  Differential effects of the calcium entry blocker D 600 on contractions of rat and guinea-pig aortas, elicited by various alpha-1 adrenoceptor agonists.

Authors:  J J Beckeringh; M J Thoolen; A de Jonge; B Wilffert; P B Timmermans; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

9.  Alpha 1-adrenoceptor-mediated vasoconstriction in vivo to enantiomers of SK & F 89748-A.

Authors:  P B Timmermans; W D Matthews; R M Demarinis; J P Hieble; M J Mathy; H N Doods; M J Thoolen; A De Jonge; B Wilffert; P A Van Zwieten
Journal:  Eur J Pharmacol       Date:  1984-05-18       Impact factor: 4.432

10.  Phenoxybenzamine is more potent in inactivating alpha 1- than alpha 2-adrenergic receptor binding sites.

Authors:  K P Minneman
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

View more
  8 in total

1.  Differences between full and partial alpha-adrenoceptor agonists in eliciting phasic and tonic types of responses in the longitudinal smooth muscle of the rat portal vein.

Authors:  H R Schwietert; D Wilhelm; B Wilffert; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

2.  Influence of calcium entry blockade on alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in the forearm of hypertensive patients.

Authors:  K Jie; P van Brummelen; P Vermey; P B Timmermans; P A van Zwieten
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Inhibition of vasoconstriction to cirazoline by calcium-entry blockade after phenoxybenzamine in rat perfused hindquarters.

Authors:  C Korstanje; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

4.  A comparison of the effects of TMB-8 and nifedipine on pressor responses to alpha 1- and alpha 2-adrenoceptor agonists in pithed rats.

Authors:  M A Aleixandre; M Puerro; A Pintado
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

5.  Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats; a comparison with nifedipine.

Authors:  R E Buckingham
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

6.  Examination of the role of inhibition of cyclic AMP in alpha 2-adrenoceptor mediated contractions of the porcine isolated palmar lateral vein.

Authors:  I K Wright; R Harling; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

7.  Greater vasodepressor sensitivity to nicardipine in spontaneously hypertensive rats (SHR) compared to normotensive rats.

Authors:  J Atkinson; M Sautel; M Sonnay; J P Fluckiger; J C de Rivaz; N Boillat; M C Piton; P A Porchet; J M Armstrong; A K Fouda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-04       Impact factor: 3.000

8.  Anti-vasoconstrictor effects of the K+ channel opener cromakalim on the rabbit aorta--comparison with the calcium antagonist isradipine.

Authors:  N S Cook; S W Weir; M C Danzeisen
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.